Modafinil Dosage Guide: Protocols, Calculator & Safety
Everything you need to know about Modafinil dosing — protocols, safety, and where to buy.
Dosage Calculator
Calculate exact dosing for Modafinil.
Dosing Protocols
A defensible beginner modafinil protocol begins with obtaining the drug through legal channels — a prescription from a licensed physician for an approved or defensible off-label indication. Modafinil is a Schedule IV controlled substance in the United States and similarly regulated in most jurisdictions; obtaining it without a prescription via international online pharmacies creates legal exposure, quality-control uncertainty, and disruption to the physician-patient relationship that is part of responsible use. Patients with clear narcolepsy, shift work disorder, or OSA-residual sleepiness should be evaluated by a sleep medicine specialist and will typically receive modafinil or armodafinil as a standard option. Patients seeking off-label use for ADHD, fatigue in MS or other chronic conditions, or depression augmentation should have the underlying condition properly evaluated and the off-label rationale documented by the prescribing physician. Users seeking modafinil purely for cognitive enhancement in the absence of medical indication should recognize that most physicians will not prescribe for this purpose, and should either make an honest case to their physician for a trial (which some physicians will consider) or accept that the compound is not available through conventional medical channels for this use. Workarounds — unlicensed online pharmacies, grey-market sources — introduce risk that a responsible user should weigh carefully. Beginning dose for almost all indications is 100-200 mg once daily, taken in the morning upon waking, with or without food. Some users start at 100 mg and titrate to 200 mg after 3-7 days if the initial dose is well tolerated but insufficient; others start directly at 200 mg which is the standard adult dose for most approved indications. Dosing later than noon commonly produces insomnia that evening and should be avoided in users with sensitive sleep. The initial response to modafinil is usually apparent within 1-2 hours of the first dose, with peak effects 2-4 hours after ingestion and meaningful wakefulness-promoting activity lasting 8-12 hours. Some users experience strong initial effects that moderate after the first few days as the body adjusts; others have stable effects from the start. Side effects in the first week typically include mild headache (usually responsive to acetaminophen or ibuprofen and tending to resolve), mild nausea (often improving with food), and mild insomnia (mitigated by earlier dosing). Users should not drive, operate heavy machinery, or perform safety-critical tasks on the first day of modafinil until they know their individual response. Key questions for the first two weeks: am I getting meaningful wakefulness benefit (subjectively and on objective measures like performance at work, hours of alert functioning, ability to complete demanding cognitive tasks)? am I experiencing tolerable side effects or unacceptable side effects? am I using it appropriately (morning dosing, not daily for non-medical indications, adequate sleep outside of modafinil-day use)? am I maintaining sleep hygiene on non-modafinil days? Decision point after two weeks: continue at the effective dose if benefits clearly exceed side effects; increase to 200-400 mg daily if 100 mg was insufficient (split into 100 mg morning + 100 mg early afternoon for sustained all-day effect, or use 200 mg single morning dose); discontinue if side effects outweigh benefits or if the drug is not providing the anticipated effect. Duration considerations: for approved medical indications, daily chronic use is typical and appropriate; for off-label cognitive enhancement, many users adopt a "weekdays only" or "demanding days only" schedule to preserve drug-free sleep days and avoid psychological dependence on the drug for daily functioning. Some users adopt a "2-3 days per week maximum" rule to keep baseline cognition and sleep quality intact. Safety monitoring for beginners includes baseline blood pressure, pulse, and (for users with cardiovascular risk factors) an ECG; liver function tests if at hepatic risk; mood and anxiety assessment; sleep quality tracking. Users on hormonal contraception must use a backup non-hormonal contraceptive method during modafinil use and for at least one month after discontinuation — this is the most commonly missed modafinil interaction and has resulted in unintended pregnancies.
Intermediate modafinil users have established tolerability and benefit over at least 1-2 months of regular use, understand their personal side effect profile, and are managing the drug within a clear usage framework. Intermediate use typically involves 200-400 mg daily dosed as either a single morning dose (200 mg) or split into morning plus early afternoon (200 mg + 100-200 mg) for sustained all-day coverage. Armodafinil 150-250 mg once daily is an alternative for users wanting longer-lasting effects from a single dose — the R-enantiomer has a substantially longer half-life than racemic modafinil. Intermediate users have typically optimized several aspects of their use: timing (morning dose taken at a consistent time, typically on waking, with or without food); dose (specific dose level that provides benefit without excessive side effects); schedule (daily for medical indications; weekdays only or demanding-days-only for cognitive enhancement); stack (modafinil alone, or with well-tested adjuncts like L-Theanine 100-200 mg); and sleep hygiene (adequate sleep on non-modafinil days, modafinil-independent sleep routines, avoiding late-day dosing). At the intermediate level, considerations expand beyond initial tolerability to longer-term effects. Blood pressure and cardiovascular monitoring at 3-6 month intervals if risk factors exist or if new hypertension develops. Liver function assessment annually. Mental health check-in for anxiety, mood, or irritability changes. Bone density and other longevity markers do not appear affected by modafinil at therapeutic doses but are reasonable to monitor as part of general health oversight. Sleep assessment — are you getting adequate restorative sleep independent of modafinil? Is your sleep quality changing? Are you sleeping less than you need, relying on modafinil to compensate? The answers to these questions determine whether the intermediate protocol is sustainable or whether it needs adjustment. Drug holidays at the intermediate level are worth considering for users with off-label cognitive enhancement purposes. A 1-2 week washout period every 3-6 months reveals the user's cognitive baseline without modafinil and prevents subtle psychological dependence on the compound. Users with approved medical indications typically do not benefit from holidays because the underlying condition returns, but even they may benefit from periodic re-evaluation of dose and response with their physician. Intermediate users commonly optimize the stack. L-Theanine 100-200 mg with the modafinil dose is probably the single best-supported adjunct for anxiety-prone users. L-Tyrosine 500-2000 mg may support catecholamine synthesis during demanding cognitive periods. Choline supplementation (alpha-GPC, citicoline) is standard if racetams (Piracetam, Noopept) are part of the stack. Magnesium 200-400 mg may help with any tension or muscle tightness. Omega-3 fatty acids at 1-2 g EPA/DHA daily support general brain health and are a common baseline. Maintaining good nutrition, hydration, and a whole-foods diet provides the substrate for cognitive performance that supplements augment rather than replace. Monitoring for tolerance at the intermediate level: users with narcolepsy generally maintain benefit over years, but users with ADHD or cognitive enhancement indications may notice some dampening of subjective effect after 6-24 months. Dose escalation is not generally the answer — instead, taking drug holidays, reassessing the indication, and considering whether an alternative (armodafinil, traditional stimulants, or non-pharmacologic approaches) would be more appropriate is the rational path. Intermediate users with psychiatric history should maintain awareness of mood, anxiety, and thought patterns. Modafinil can rarely unmask mania in bipolar disorder or worsen anxiety in vulnerable users, and these effects may emerge at the intermediate timescale rather than immediately. Any new or worsening psychiatric symptoms should prompt reassessment of the protocol with the prescribing physician. The intermediate user has also typically worked out the non-pharmacologic components that support cognitive function: consistent sleep schedule (7-9 hours), regular exercise (both aerobic and resistance), stress management practices, adequate nutrition, and meaningful social and recreational engagement. Modafinil is a performance enhancement overlaid on these fundamentals, not a replacement for them.
Advanced modafinil protocols are used by long-term users with well-characterized individual response, robust clinical oversight, and sophisticated understanding of how modafinil fits into broader cognitive and health optimization. Advanced dosing typically falls within the approved range of 100-400 mg daily; higher doses (up to 600 mg) have been studied but are not standard and produce more side effects without necessarily more cognitive benefit. Some advanced users cycle between modafinil and armodafinil to take advantage of different pharmacokinetic profiles — armodafinil for days requiring sustained 12+ hour cognitive performance, modafinil for days requiring strong acute morning performance with earlier offset allowing timely evening sleep. Advanced users are commonly integrating modafinil into comprehensive protocols that address multiple dimensions of cognition, performance, and health. A typical advanced cognitive performance stack might include: modafinil 100-200 mg morning (weekdays only); L-Theanine 100-200 mg with the modafinil dose; L-Tyrosine 1-2 g on cognitively demanding days; alpha-GPC or citicoline 300-500 mg daily; Noopept 10-30 mg daily; Lion's Mane 500-1000 mg daily; Uridine Monophosphate 150-300 mg daily with DHA 1-2 g; Methylene Blue 0.5-2 mg/kg daily; NAD+ precursors (NR 500-1000 mg or NMN 500-1000 mg); magnesium threonate 1-2 g at night; omega-3 fatty acids 2-3 g daily; and vitamin D, B-complex, and other baseline micronutrients as indicated by labs. This comprehensive stack represents the high end of nootropic sophistication and introduces all of the attribution-loss concerns that apply to complex regimens. Users who pursue advanced stacks should recognize they cannot easily identify which compound is driving which effect, which limits ability to optimize the stack over time. Advanced users frequently pair modafinil with peptide protocols that address different dimensions of performance and wellness. CJC-1295 + Ipamorelin or Tesamorelin support GH/IGF-1 and sleep quality; BPC-157 and TB-500 support recovery and injury healing; Epithalon for longevity-oriented use; Selank and Semax for complementary nootropic effects; DSIP for sleep support. These peptide additions occur within a broader protocol design rather than as simple modafinil adjuncts. Monitoring at the advanced level should be comprehensive. Quarterly labs: comprehensive metabolic panel, liver function tests with GGT and alkaline phosphatase, CBC with differential, lipid panel with ApoB and Lp(a), HbA1c and fasting insulin, TSH with free T3 and free T4, comprehensive hormone panel, vitamin D, B12, folate, homocysteine, inflammatory markers. Annual: ECG, consideration of echocardiogram if prolonged cardiovascular exposure, consideration of carotid imaging, DEXA body composition, age-appropriate cancer screening. Cognitive performance tracking: standardized cognitive tests (Dual N-back, digit span, processing speed tasks) at quarterly intervals to detect both tolerance and any cognitive decline; subjective tracking of work performance, mood, motivation, creativity, and other functional outcomes. Sleep tracking via consumer wearables provides daily data on sleep quality, which is critical for modafinil users given the sleep-wake tradeoff. Heart rate variability and resting heart rate trends can detect cardiovascular strain from the drug. Advanced users should have sophisticated stopping criteria. Specific thresholds — sustained BP elevation, new anxiety or mood symptoms, unexplained rash, any laboratory abnormality — should prompt dose reduction or discontinuation. Advanced users are also in a position to contribute data to research. Anonymized n=1 data sharing with nootropic communities, participation in clinical trials for off-label indications, and structured self-experimentation with clear hypotheses can provide information that benefits the broader user community. Protocol exit planning is important. Long-term modafinil use for cognitive enhancement does not need to be lifelong. Life circumstances change — career transitions, retirement, different cognitive demands — and the drug that was appropriate for one phase may not fit another. Planned de-escalation with dose reduction over 2-4 weeks followed by extended drug-free periods can reset the user's baseline and clarify whether continued use remains justified. Users who have relied on modafinil for years may experience a period of reduced subjective cognitive sharpness for 2-6 weeks after discontinuation; this typically normalizes without intervention. The overall theme at the advanced level is that modafinil remains a specific pharmacologic intervention within a comprehensive cognitive and health optimization framework, that the drug does real work but is not a panacea, and that the sophistication of the surrounding protocol should match or exceed the sophistication of the drug itself.
Commonly Stacked With
Modafinil is frequently combined with other cognitive enhancement and wellness compounds. The most common and evidence-supported stacks involve buffering against modafinil's common side effects and complementing its mechanism with compounds that support different aspects of cognition. The classic stack partner is L-Theanine at 100-200 mg, typically taken alongside the modafinil dose. Theanine is an amino acid from tea that modestly enhances alpha wave activity, promotes calm alertness, and can blunt modafinil's anxiety or jitteriness without reducing its cognitive effects. This combination is particularly useful for anxiety-prone users or those who experience over-arousal on modafinil alone. Caffeine combinations are widespread but less clearly beneficial — small doses of caffeine (50-100 mg) may synergize with modafinil on vigilance measures, but larger caffeine doses compound the cardiovascular and anxiety effects and often worsen the overall experience. Users who tolerate caffeine well at baseline should consider reducing rather than maintaining their caffeine intake when starting modafinil. L-Tyrosine at 500-2000 mg is commonly stacked with modafinil because tyrosine is the amino acid precursor to dopamine and norepinephrine, and supplementation may support catecholamine synthesis during periods of intense cognitive demand. Evidence for tyrosine independently is modest but positive for cognitive performance under stress and sleep deprivation; combination with modafinil may provide complementary catecholamine support without mechanism overlap. With racetam nootropics — Piracetam, Noopept, phenylpiracetam, aniracetam, oxiracetam — stacking is common in nootropic communities. The rationale is that racetams modulate cholinergic and glutamatergic transmission, which is complementary to modafinil's dopaminergic and orexinergic effects. Evidence for synergy is anecdotal rather than clinical, but the mechanistic rationale is reasonable and the safety profile of the combination is generally favorable. Users should pay attention to headache, which is a common side effect of both modafinil and racetams (the latter typically attributed to acetylcholine depletion) and may be additive. Co-supplementation with choline sources (alpha-GPC 300-600 mg or citicoline 250-500 mg) is standard when stacking racetams with modafinil. With Bromantane, the Russian actoprotector, the combination targets different mechanisms of fatigue resistance — modafinil's orexinergic/dopaminergic wakefulness versus bromantane's dopaminergic/neurosteroidogenic resilience — and some users report the combination provides sustained cognitive enhancement with better subjective tolerability than modafinil alone. Evidence is anecdotal. With Selank and Semax, the Russian peptide nootropics, the combination combines modafinil's stimulant-adjacent wakefulness with the anxiolytic and neurotrophic effects of the peptides. Selank in particular may blunt the anxiety sometimes produced by modafinil while maintaining cognitive benefit. With Sulbutiamine, the lipid-soluble thiamine derivative used in some countries for asthenia, the combination may support cognitive energy through different mechanisms — sulbutiamine enhances cerebral thiamine and dopaminergic function while modafinil drives orexinergic and dopaminergic wakefulness. The combination is used by some nootropic stack designers but has no formal clinical evaluation. With Noopept specifically, users often report complementary effects — noopept for memory and cognitive consolidation, modafinil for sustained attention and vigilance — though the combination has not been clinically studied. With Methylene Blue at low doses (0.5-2 mg/kg), the combination provides mitochondrial electron transport support alongside modafinil's neurotransmitter effects. Some users report enhanced subjective cognitive performance on this combination; mechanistic rationale is coherent though unproven clinically. With NAD+ precursors (NR, NMN) at standard supplement doses, the combination targets cellular energy metabolism alongside modafinil's vigilance effects. With Lion's Mane, the nerve growth factor-promoting medicinal mushroom, the combination provides neurotrophic support alongside acute wakefulness. Neither evidence for synergy nor safety concerns exist in the literature. With Uridine Monophosphate for phosphatidylcholine synthesis and dopaminergic tone support, the combination is used within the broader dopaminergic nootropic framework. With GH secretagogues (CJC-1295, Ipamorelin), no direct interactions but the cognitive performance focus of modafinil pairs well with sleep and recovery optimization from GH peptides. With weight loss and metabolic compounds (Semaglutide, Tirzepatide), modafinil is sometimes used as a cognitive counter to GLP-1-associated fatigue or brain fog, though systematic evidence for this use is limited. Combinations to avoid or approach with caution: classical stimulants (amphetamines, methylphenidate, ephedrine, high-dose caffeine) compound cardiovascular load and anxiety without substantial cognitive synergy; MAO inhibitors have theoretical risk of serotonin syndrome though modafinil's direct serotonergic effects are modest; other medications with seizure-threshold-lowering properties should be combined carefully; and other CYP3A4-inducing medications may produce cumulative effects on contraceptive and other substrate levels. The overall principle for modafinil stacking is that modafinil alone is a complete cognitive enhancement intervention for many users — adding additional compounds introduces attribution loss, compound side effects, and cost without necessarily improving outcomes. Users should establish their response to modafinil alone before introducing stack elements and should add only one compound at a time to preserve attribution.
Side Effects & Safety
Contraindications
Modafinil has a well-defined contraindication profile from 25+ years of clinical use and complete FDA labeling. Absolute contraindications include: known hypersensitivity to modafinil, armodafinil, or any component of the formulation; history of severe cutaneous drug reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS syndrome) to modafinil, armodafinil, or chemically similar compounds; severe hypersensitivity, angioedema, or anaphylactic reactions with prior use. These hypersensitivity contraindications exist because recurrence on rechallenge is potentially life-threatening. Serious cardiovascular contraindications include: recent myocardial infarction or unstable angina within the past 6 months; serious cardiac arrhythmias including atrial fibrillation with rapid ventricular response, ventricular tachycardia, or symptomatic bradyarrhythmias; severe uncontrolled hypertension; left ventricular hypertrophy; mitral valve prolapse with previous mitral valve prolapse syndrome on CNS stimulants; and recent history of ischemic ECG changes, chest pain, or arrhythmia. Modafinil's modest cardiovascular effects (small increases in heart rate and blood pressure) are well-tolerated in most users but may be significant in patients with cardiovascular instability. Patients with stable, well-controlled cardiovascular disease may use modafinil with physician oversight and monitoring. Pregnancy is a significant consideration. Modafinil crosses the placenta and animal studies have shown developmental toxicity at high doses. The FDA previously classified modafinil as Category C and labels now advise that it should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Pregnancy registries have collected limited data suggesting possible increased risk of congenital malformations and intrauterine growth restriction with modafinil exposure, leading to a 2019 FDA safety advisory recommending women of reproductive potential use reliable non-hormonal contraception during treatment. Pregnancy is a relative to strong contraindication unless the indication is compelling (severe narcolepsy affecting maternal safety) and alternative management is insufficient. Breastfeeding should be avoided or the infant monitored carefully — modafinil is excreted in breast milk at low concentrations and effects on the nursing infant are not fully characterized. Children and adolescents should not use modafinil because Stevens-Johnson syndrome has appeared at higher rates in pediatric trials, leading to withdrawal of pediatric indication from the label. Severe hepatic impairment requires dose reduction (typically halved) but is a relative contraindication for full-dose use. Severe renal impairment does not contraindicate use but warrants monitoring. Psychiatric history requires careful evaluation. History of psychosis, severe mania, or schizophrenia are relative to absolute contraindications depending on current stability — modafinil can rarely unmask psychotic symptoms. History of severe anxiety, panic disorder, or significant anxiety-inducing medications may be exacerbated. Bipolar disorder has reports of modafinil-induced mania in case series, though it is also used in some bipolar depression augmentation protocols under psychiatric oversight. Bipolar patients should use modafinil only under psychiatric supervision with careful monitoring. History of suicidal ideation or behavior is a relative contraindication due to rare reports of emergent suicidal ideation on modafinil. Substance use disorder history is a relative contraindication. While modafinil has lower abuse potential than classical stimulants, it is still a controlled substance and users with active or recent substance use disorder should use it only with specialist oversight. Concurrent use with classical stimulants, other Schedule IV substances, or with medications having significant CYP3A4/CYP2C19 interactions warrants specific caution. Drug interactions of clinical importance include: hormonal contraception — modafinil reduces efficacy and backup non-hormonal contraception is required during treatment and for one month after; cyclosporine, sirolimus, tacrolimus — modafinil may reduce levels requiring dose adjustment; antiepileptic drugs (phenytoin, carbamazepine) — complex interactions with modafinil may require TDM; warfarin — possible INR effects requiring more frequent monitoring; benzodiazepines, tricyclic antidepressants — possible level elevations through CYP2C19 inhibition; MAO inhibitors — theoretical serotonin syndrome risk though modafinil's direct serotonergic effects are modest; and classical stimulants — additive cardiovascular and psychiatric effects. Absence of appropriate clinical oversight is the final contraindication. Modafinil should be obtained through a prescription from a licensed physician who has evaluated the indication, assessed contraindications, discussed risks and benefits, and is available for ongoing monitoring and management. Self-prescribing without appropriate medical infrastructure is not responsible use of a Schedule IV medication with real adverse effect potential.
Additional Notes
Modafinil is dosed orally. The tablets (100 mg and 200 mg in the US; other strengths in other markets) are typically taken whole with water, with or without food. Food modestly slows absorption but does not reduce total exposure significantly. The standard adult dose across approved indications is 200 mg once daily taken in the morning for narcolepsy, OSA, and general cognitive enhancement use. For shift work sleep disorder, 200 mg is taken 30-60 minutes before the start of the shift. Higher doses (up to 400 mg daily, split into morning and early afternoon) are sometimes used for severe daytime sleepiness that does not respond adequately to 200 mg, though clinical trials have shown inconsistent additional benefit above 200 mg for most patients. Armodafinil (the R-enantiomer, brand name Nuvigil) is dosed 150 mg or 250 mg once daily, with the 150 mg dose generally providing equivalent clinical effect to modafinil 200 mg due to the longer half-life. Pediatric use is not FDA-approved and is not standard due to Stevens-Johnson syndrome concerns from pediatric trials. Geriatric patients (>65 years) may have reduced modafinil clearance and should typically start at 100 mg daily with dose titration based on response and tolerability. Hepatic impairment requires dose reduction — severe hepatic impairment reduces clearance by approximately 60%, and the typical recommendation is to halve the standard dose (100 mg daily instead of 200 mg) with titration as tolerated. Significant renal impairment does not require dose adjustment because renal clearance is minor. Timing is important. Morning dosing (immediately upon waking or within an hour) provides wakefulness throughout the waking day with minimal sleep interference. Afternoon dosing (after 2 PM) commonly produces insomnia and should be avoided unless the dose is intentional for shift work or other specific circumstances requiring overnight wakefulness. Split dosing (e.g., 100 mg morning + 100 mg noon) provides more sustained all-day coverage than a single morning dose for users needing this profile. The specific split timing should be adjusted to the individual's work schedule and sleep timing. Missed doses should generally be skipped if more than a few hours past the intended dose time, rather than taken late and risking disrupted sleep that night. Double dosing to compensate for missed doses is not recommended. Onset of effects occurs within 1-2 hours of oral ingestion, with peak effects at 2-4 hours and meaningful wakefulness-promoting activity persisting 8-12 hours for modafinil (longer for armodafinil). Individual variability in metabolism — influenced by CYP3A4 activity, age, liver function, and other factors — produces differences in both onset speed and duration between users. Tolerance to the wakefulness effect is minimal over chronic use for most users; tolerance to cognitive enhancement effects may be somewhat more variable. Discontinuation syndrome is typically absent or mild — most users can stop modafinil without taper, though some experience a few days of fatigue or mild depression as the body re-establishes baseline wakefulness. Users on chronic high doses may benefit from a brief taper over 1-2 weeks. Overdose risk with modafinil is lower than with classical stimulants. Ingestion of 1,200-4,500 mg (far above therapeutic doses) has produced excitation, agitation, insomnia, anxiety, tachycardia, and hypertension but has not typically been life-threatening in healthy adults. Management of overdose is supportive. Cardiac monitoring is warranted for very large ingestions or in users with cardiovascular disease. Drug screening considerations: modafinil does not cross-react with standard urine drug screens for amphetamines, opioids, cocaine, or other common substances. Specific testing for modafinil is possible but not routine. Athletes should note that modafinil is prohibited by the World Anti-Doping Agency (WADA) as a stimulant under Class S6, and competing athletes should be aware of this status and obtain therapeutic use exemptions if medically indicated. Storage: modafinil tablets are stable at room temperature (20-25°C) with protection from moisture. No special storage requirements beyond standard medication handling. Generic modafinil has been available since 2012 in the US following the expiration of Cephalon's patent, and generic prices are substantially lower than brand-name Provigil — generic modafinil 200 mg typically costs $1-3 per tablet at US pharmacies with insurance, compared to $30-50 for brand Provigil. Armodafinil generic is similarly available and priced. International generic modafinil (Modalert, Modvigil from Indian manufacturers) is less expensive but its legal availability varies by jurisdiction; in the US, importing modafinil without a prescription is technically illegal even for personal use, though enforcement has been inconsistent.
Frequently Asked Questions
What is the recommended Modafinil dosage?
Dosage for Modafinil varies by protocol. Consult a qualified healthcare provider.
How often should I take Modafinil?
Administration frequency depends on the specific protocol. Consult current research literature.
Does Modafinil need to be cycled?
Cycling requirements depend on the protocol. Follow established research guidelines.
What are Modafinil side effects?
Modafinil's side effect profile is relatively favorable compared to classical stimulants but is not negligible. The most common side effects, reported in 5-10% or more of users in clinical trials, are headache (dose-related, typically transient but occasionally persistent enough to require discontinuation), nausea (usually mild, often improving after the first week), nervousness or anxiety (particularly at higher doses or in anxiety-prone users), insomnia (mitigated by taking the dose earlier in the day), dry mouth, diarrhea or constipation, dizziness, and dyspepsia. These mild side effects are generally manageable and rarely prompt discontinuation in users who otherwise benefit from the drug. Cardiovascular effects are worth specific attention. Modafinil produces small but consistent increases in heart rate and blood pressure in clinical trials, with mean increases of 2-5 bpm in heart rate and 1-3 mmHg in blood pressure — modest effects but potentially significant in users with pre-existing hypertension, arrhythmias, or cardiovascular disease. Reports of chest pain, palpitations, and arrhythmias exist in post-marketing surveillance, though these are uncommon. Users with significant cardiovascular disease should have medical oversight before and during modafinil use, with periodic BP monitoring. Psychiatric side effects include anxiety, irritability, mood changes, and in rare cases more severe events including mania, psychosis, suicidal ideation, and panic attacks. The rate of serious psychiatric adverse events is low but real — the FDA label includes warnings about these events, and patients with a history of psychiatric disorders (particularly bipolar disorder, psychotic disorders, or anxiety disorders) should use modafinil only under psychiatric supervision. The most clinically important rare serious adverse events are severe cutaneous reactions: Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS). These immune-mediated skin reactions are rare — estimated incidence on the order of 1 per 1,000,000 prescriptions based on post-marketing data — but can be life-threatening when they occur. FDA reporting led to a black box warning regarding pediatric use (where SJS appeared more common in one trial) and to general advisories that users should discontinue modafinil immediately and seek medical evaluation for any unexplained rash, skin peeling, mucosal involvement, fever with rash, or blistering. Users with a prior history of severe cutaneous drug reactions to any medication should not use modafinil. Rare but serious angioedema and anaphylactoid reactions have also been reported. Hepatic effects are usually minimal but rare cases of significant transaminase elevations have occurred. Hematologic effects are rare but include reports of thrombocytopenia and agranulocytosis in isolated cases. Drug interactions are a major category of modafinil side effects. Through CYP3A4 induction, modafinil significantly reduces the plasma concentrations of substrates metabolized by this enzyme, including hormonal contraceptives (combined oral contraceptives, progestin-only pills, hormonal implants, hormonal IUDs to a lesser extent), cyclosporine, certain HIV medications, some anticonvulsants, and many others. The contraceptive interaction is particularly important: modafinil reduces the efficacy of hormonal birth control, and women using modafinil should use a backup non-hormonal method during treatment and for at least one month after discontinuation. Failure to communicate this interaction has resulted in unintended pregnancies. Through CYP2C19 inhibition, modafinil can increase levels of substrates such as phenytoin, diazepam, propranolol, omeprazole, and certain tricyclic antidepressants, potentially producing clinical effects requiring dose adjustment of the coadministered medication. Modafinil may also affect warfarin levels through uncertain mechanisms; patients on warfarin should have more frequent INR monitoring when starting or stopping modafinil. Abuse potential and tolerance are lower for modafinil than for amphetamines or methylphenidate but not zero. The DEA Schedule IV classification reflects genuine but limited abuse potential. Subjective effects are generally less reinforcing than those of stimulants — users describe modafinil as producing focused alertness without strong euphoria — and withdrawal symptoms after discontinuation are mild or absent in most users. However, users with a history of substance use disorder should exercise caution, and some users develop psychological dependence on modafinil as a work aid even without classical physical dependence. Tolerance to modafinil's wakefulness effect is minimal over months to years of clinical use, which is one of its distinguishing features — patients with narcolepsy on chronic modafinil generally maintain benefit without dose escalation. Tolerance to its cognitive enhancement effects in healthy users may be somewhat more variable, with some users reporting diminished subjective benefit over time, though objective cognitive performance effects appear more durable. Sleep effects are important to consider. Modafinil taken late in the day commonly produces insomnia; the standard practice is morning dosing only, with a second dose (if used) taken no later than early afternoon. Users with pre-existing sleep disturbance should address sleep hygiene before introducing modafinil. Subjectively normal daytime alertness on modafinil does not replace the restorative functions of actual sleep, and chronic use to compensate for inadequate sleep incurs the health consequences of sleep deprivation regardless of subjective alertness.
Where can I buy Modafinil?
Visit our vendor directory to find trusted sources for Modafinil.
Free 2026 Peptide Cheat Sheet — 50 pages, PDF
Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.
